
    
      Primary Objective: To determine the rate of graft versus host disease (GvHD) free, relapse
      free survival (GRFS) at one year following CD34 selected allogeneic hematopoietic cell
      transplantation using myeloablative conditioning combined with an infusion of phenotypic CD8+
      memory T cells from human leukocyte antigen (HLA) matched donors for patients with
      myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or acute lymphoblastic leukemia
      (ALL).

      Secondary Objective: To determine the rate of graft rejection, acute and chronic GvHD, non
      relapse mortality, relapse, overall survival, and disease free survival.
    
  